The DOI matches its Crossref record.
The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials
Abstract
The cognitive subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog) is used as an efficacy measure in clinical drug trials of Alzheimer's disease (AD). We used data from 1,648 AD participants in two identical 26-week multicenter drug trials to examine the distribution of baseline ADAS-Cog scores in relation to selected demographic and clinical variables, Mini-Mental State Exam (MMSE), Global Deterioration Scale (GDS), and Geriatric Evaluation by Relative's Rating Instrument (GERRI) scores. At baseline, the mean (+/-SD) MMSE score was 18 +/- 4, the ADAS-Cog score was 28 +/- 11, and most subjects were in GDS stage 4 or 5. The ADAS-Cog score was statistically significantly correlated with MMSE (R = -0.76, p < 0.0001) and GERRI (R = 0.40, p < 0.0001) total scores. Correlations among the ADAS-Cog items ranged from 0.19 to 0.59 and all were statistically significant (p < 0.0001). In a multiple regression model, younger age, male gender, older age at onset of dementia, use of concurrent estrogen, and use of concurrent anti-inflammatory agents were statistically significantly associated with superior cognitive performance. We also present data on the distribution of ADAS-Cog scores in relation to subjects' age, level of education, MMSE score, and GDS stage. Because age, MMSE score, and GDS stage (and not the ADAS-Cog) are commonly used to select subjects for AD clinical trials, our data should improve the ability of sponsors to predict ADAS-Cog scores of the subjects in their trials on the basis of the inclusion criteria used. Our data also suggest that age, gender, age at onset of dementia, level of education, and use of estrogen (in women) or anti-inflammatory drugs are related to cognitive abilities in AD. Further studies are needed to assess how and when cognitive differences related to these variables arise.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Estrogen for Alzheimer’s disease in women: Randomized, double-blind, placebo-controlled trial
Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R. A., Hake, A. M., & Farlow, M. R. (2000) · Neurology · doi:10.1212/wnl.54.2.295 · Cited by 550
Sex differences in cognitive impairment and Alzheimer’s disease
Li, R., & Singh, M. (2014) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.01.002 · Cited by 527
Hogervorst, E., Williams, J., Budge, M., Riedel, W., & Jolles, J. (2000) · Neuroscience · doi:10.1016/s0306-4522(00)00410-3 · Cited by 439
Berchtold, N. C., & Cotman, C. W. (1998) · Neurobiology of Aging · doi:10.1016/s0197-4580(98)00052-9 · Cited by 430
Pike, C. J. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.721552.x · Cited by 387
Metadata
- Authors
- Doraiswamy, P. M., Bieber, F., Kaiser, L., Krishnan, K. R., Reuning-Scherer, J., & Gulanski, B.
- Venue
- Neurology
- Published
- 1997-06
- Volume
- 48
- Issue
- 6
- Pages
- 1511-1517
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2089675476
- Cited by
- 165
- References
- 0
- FWCI
- 7.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. https://app.cochat.ai/papers/10.1212/wnl.48.6.1511
- The paper
- Doraiswamy, P. M., Bieber, F., Kaiser, L., Krishnan, K. R., Reuning-Scherer, J., & Gulanski, B. (1997). The Alzheimer's disease assessment scale: Patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. https://doi.org/10.1212/wnl.48.6.1511
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.